Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions
Top Cited Papers
Open Access
- 13 February 2023
- journal article
- review article
- Published by Springer Nature in BMC Medicine
- Vol. 21 (1) , 1-5
Abstract
Atrial fibrillation (AF) and heart failure (HF) are frequently associated and can be caused or exacerbated by each other through different mechanisms. AF is particularly common in patients with heart failure with preserved ejection fraction (HFpEF) defined as left ventricular ejection fraction (LVEF) ≥ 50%, with a prevalence ranging around 40–60%.In two recent trials, treatment with SGLT2 inhibitors resulted in a lower risk of worsening heart failure or cardiovascular death than placebo in patients with HFpEF, and SGLT2 inhibitors similarly improved prognosis whether patients had AF or not at enrolment. Analyses for subgroups of interest of patients with HFpEF likely to be at higher risk of AF (particularly those with older age or obesity) similarly indicated a consistent benefit with SGLT2 inhibitors. That subgroup in patients with HFpEF is those with a history of previous HF with LVEF ≤ 40%. The EAST-AFNET 4 trial indicated that early rhythm-control therapy was associated with a lower risk of adverse cardiovascular outcomes than usual care among patients with recent AF and cardiovascular conditions, including those with HF. In patients with AF and HF included in the CABANA trial, catheter ablation produced marked improvements in survival, freedom from AF recurrence, and quality of life compared to drug therapy. When strategies aiming at rhythm control eventually fail in patients with AF and HFpEF, a strategy of rate control with atrioventricular junction ablation and cardiac resynchronisation should be discussed since it may also reduce all-cause mortality.Finally, and in conclusion, considering that patients with AF and HFpEF may have a variety of cardiovascular and non-cardiovascular additional comorbidities, they are among those likely to have the highest clinical benefit being adherent to a holistic and integrated care management of AF following the ABC (Atrial Fibrillation Better Care) pathway.Keywords
This publication has 19 references indexed in Scilit:
- AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trialEuropean Heart Journal, 2021
- Adherence to the ‘Atrial Fibrillation Better Care’ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 PatientsThrombosis and Haemostasis, 2021
- Ablation Versus Drug Therapy for Atrial Fibrillation in Heart FailureCirculation, 2021
- Early Rhythm-Control Therapy in Patients with Atrial FibrillationNew England Journal of Medicine, 2020
- The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular eventsEP Europace, 2019
- Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS)EP Europace, 2019
- Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term RegistryEuropean Heart Journal, 2018
- Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection FractionJACC, 2017
- The ABC pathway: an integrated approach to improve AF managementNature Reviews Cardiology, 2017
- Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection FractionJACC: Heart Failure, 2017